Oxymetazoline
- oxymetazoline
- 1491-59-4
- Oxymethazoline
- Hazol
- Oximetazolinum
- Create:2005-03-25
- Modify:2025-01-04
- Hydrochloride, Oxymetazoline
- Oxymetazoline
- Oxymetazoline Hydrochloride
- oxymetazoline
- 1491-59-4
- Oxymethazoline
- Hazol
- Oximetazolinum
- Oxylazine
- Rhinofrenol
- Iliadin
- Sinerol
- Nafrine
- Navisin
- Nezeril
- Oxymetozoline
- Oxymetazolinum
- Oximetazolina
- Rhinolitan
- Afrin
- 6-tert-Butyl-3-(4,5-dihydro-1H-imidazol-2-ylmethyl)-2,4-dimethylphenol
- Nasacon
- Operil
- Phenol, 3-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethyl-
- 6-t-Butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol
- HSDB 3143
- 2-(4-tert-Butyl-2,6-dimethyl-3-hydroxybenzyl)-2-imidazoline
- Oxymetazolinum [INN-Latin]
- Oximetazolina [INN-Spanish]
- 6-tert-Butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol
- oxymetazolina
- H 990
- UNII-8VLN5B44ZY
- EINECS 216-079-1
- 8VLN5B44ZY
- BRN 0886303
- CHEBI:7862
- Oxymetazoline (INN)
- Phenol, 3-((4,5-dihydro-1H-imidazol-2-yl)methyl)-6-(1,1-dimethylethyl)-2,4-dimethyl-
- DTXSID3040691
- Phenol, 6-tert-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethyl-
- 3-[(4,5-Dihydro-1H-imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethylphenol
- DTXCID1020691
- Navasin
- Phenol, 6-t-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethyl-
- Vicks Sinex
- NCGC00015766-08
- OXYMETAZOLINE [INN]
- Oxymetazolinum (INN-Latin)
- Oximetazolina (INN-Spanish)
- Oxymetazoline [INN:BAN]
- CAS-1491-59-4
- Operil (TN)
- oxymetazoline hydrochloride crystalline
- 6-tert-butyl-3-((4,5-dihydro-1H-imidazol-2-yl)methyl)-2,4-dimethylphenol
- 6-tert-Butyl-3-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-2,4-dimethylphenol
- 3-((4,5-dihydro-1H-imidazol-2-yl)methyl)-6-(1,1-dimethylethyl)-2,4-dimethylphenol
- Nasivine (Salt/Mix)
- Spectrum_001051
- Tocris-1142
- Prestwick0_000224
- Prestwick1_000224
- Prestwick2_000224
- Prestwick3_000224
- Spectrum2_000998
- Spectrum3_000533
- Spectrum4_000464
- Spectrum5_001114
- Lopac-O-2378
- OXYMETAZOLINE [MI]
- Biomol-NT_000161
- CHEMBL762
- OXYMETAZOLINE [HSDB]
- Lopac0_000903
- SCHEMBL24301
- BSPBio_000267
- BSPBio_002145
- GTPL124
- KBioGR_000908
- KBioSS_001531
- OXYMETAZOLINE [VANDF]
- cid_66259
- DivK1c_000567
- SPBio_001095
- SPBio_002188
- OXYMETAZOLINE [WHO-DD]
- BPBio1_000295
- BPBio1_000419
- BDBM30712
- KBio1_000567
- KBio2_001531
- KBio2_004099
- KBio2_006667
- KBio3_001645
- A14AA05
- R01AA05
- R01AB07
- S01GA04
- NINDS_000567
- HMS2089G03
- ALBB-036521
- Tox21_110217
- STK075254
- 3-(4,5-dihydro-1H-imidazol-2-ylmethyl)-2,4-dimethyl-6-tert-butyl-phenol
- AKOS007930348
- Tox21_110217_1
- AC-6370
- CAS-151615
- CCG-204985
- DB00935
- SDCCGSBI-0050878.P005
- IDI1_000567
- NCGC00015766-01
- NCGC00015766-02
- NCGC00015766-03
- NCGC00015766-04
- NCGC00015766-05
- NCGC00015766-06
- NCGC00015766-07
- NCGC00015766-09
- NCGC00015766-10
- NCGC00015766-11
- NCGC00015766-13
- NCGC00015766-16
- NCGC00015766-21
- NCGC00022345-02
- NCGC00022345-04
- NCGC00022345-05
- NCGC00022345-06
- HY-12722
- SBI-0050878.P004
- CS-0012298
- H-990
- NS00005342
- C07363
- D08322
- G78135
- AB00053513-12
- AB00053513-13
- AB00053513_14
- AB00053513_15
- EN300-23521946
- L000459
- Q417813
- BRD-K16195444-001-01-7
- BRD-K16195444-003-16-1
- BRD-K16195444-003-24-5
- BRD-K16195444-003-25-2
- BRD-K16195444-003-26-0
- 6-tert-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethyl-phenol;hydrochloride
- 6-tert-Butyl-3-(4,5-dihydro-1H-imidazol-2-ylmethyl)-2,4-dimethylphenol #
- 6-tert-butyl-3-(4,5-dihydro-1H-imidazol-2-ylmethyl)-2,4-dimethyl-phenol;hydrochloride
- Phenol, 6-tert-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethyl- (7CI,8CI)
- Phenol, 3-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethyl- (9CI)
168.16 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
160.2 Ų [M+K]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
162.92 Ų [M+H-H2O]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
163.86 Ų [M+Na]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
261.1965 999
205.1343 399
177.1277 34
191.1429 27
135.0808 25
135.0815 999
231.1491 826
161.0967 748
205.1336 645
105.071 493
S - Sensory organs
S01 - Ophthalmologicals
S01G - Decongestants and antiallergics
S01GA - Sympathomimetics used as decongestants
S01GA04 - Oxymetazoline
R - Respiratory system
R01 - Nasal preparations
R01A - Decongestants and other nasal preparations for topical use
R01AA - Sympathomimetics, plain
R01AA05 - Oxymetazoline
- Extracellular
- Membrane
Use (kg; approx.) in Germany (2009): >10
Consumption (g per capita; approx.) in Germany (2009): 0.000122
Calculated removal (%): 86.2
H300+H330 (96.6%): Fatal if swallowed or if inhaled [Danger Acute toxicity, oral; acute toxicity, inhalation]
H300 (100%): Fatal if swallowed [Danger Acute toxicity, oral]
H318 (100%): Causes serious eye damage [Danger Serious eye damage/eye irritation]
H330 (100%): Fatal if inhaled [Danger Acute toxicity, inhalation]
H412 (100%): Harmful to aquatic life with long lasting effects [Hazardous to the aquatic environment, long-term hazard]
P260, P264, P264+P265, P270, P271, P273, P280, P284, P301+P316, P304+P340, P305+P354+P338, P316, P317, P320, P321, P330, P403+P233, P405, and P501
(The corresponding statement to each P-code can be found at the GHS Classification page.)
Aggregated GHS information provided per 29 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.
Acute Tox. 1 (100%)
Eye Dam. 1 (100%)
Acute Tox. 1 (100%)
Aquatic Chronic 3 (100%)
◉ Summary of Use during Lactation
Although no information exists on the use of oxymetazoline specifically during breastfeeding, very little should reach the infant through breastmilk because of the local administration and limited absorption into the maternal bloodstream. It is recommended over oral systemic decongestants such as pseudoephedrine during breastfeeding. Topical use on the face for rosacea is unlikely to present a risk to the nursing infant.
◉ Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
◉ Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
◈ What is oxymetazoline?
Oxymetazoline is a medication in nasal sprays (sprayed into nostrils) and topical preparations (applied to skin). Oxymetazoline has been used to treat nasal congestion, eye inflammation, and skin redness. It works by making the blood vessels narrower (constricting blood vessels). Oxymetazoline can be found in prescription products and in many over the counter products, such as Afrin®, Dristan®, Nostrilla®, Rhofade®, and Vicks®.Sometimes when people find out they are pregnant, they think about changing how they take their medication, or stopping their medication altogether. However, it is important to talk with your healthcare providers before making any changes to how you take your medication. Your healthcare providers can talk with you about the benefits of treating your condition and the risks of untreated illness during pregnancy.
◈ I take oxymetazoline. Can it make it harder for me to get pregnant?
It is not known if oxymetazoline can make it harder to get pregnant.
◈ Does taking oxymetazoline increase the chance for miscarriage?
Miscarriage is common and can occur in any pregnancy for many different reasons. Studies have not been done to see if oxymetazoline increases the chance for miscarriage.
◈ Does taking oxymetazoline increase the chance of birth defects?
Every pregnancy starts out with a 3-5% chance of having a birth defect. This is called the background risk. Oxymetazoline is not expected to increase the chance of birth defects above the background risk.
◈ Does taking oxymetazoline in pregnancy increase the chance of other pregnancy-related problems?
Studies have not been done to see if oxymetazoline increases the chance for pregnancy-related problems such as preterm delivery (birth before week 37) or low birth weight (weighing less than 5 pounds, 8 ounces [2500 grams] at birth).A report of 12 pregnancies in healthy people exposed to a one-time nasal spray dose of oxymetazoline showed no effect on uterine blood flow.
◈ Does taking oxymetazoline in pregnancy affect future behavior or learning for the child?
Studies have not been done to see if oxymetazoline can cause behavior or learning issues for the child.
◈ Breastfeeding while taking oxymetazoline:
Oxymetazoline has not been well-studied for use while breastfeeding. Since oxymetazoline is sprayed into the nose or rubbed onto skin, it is thought that very little of the medication passes into breastmilk. Be sure to talk to your healthcare provider about all your breastfeeding questions.
◈ If a male takes oxymetazoline, could it affect fertility (ability to get partner pregnant) or increase the chance of birth defects?
Studies have not been done to see if oxymetazoline could affect male fertility or increase the chance of birth defects above the background risk. In general, exposures that fathers or sperm donors have are unlikely to increase risks to a pregnancy. For more information, please see the MotherToBaby fact sheet Paternal Exposures at https://mothertobaby.org/fact-sheets/paternal-exposures-pregnancy/.
Patents are available for this chemical structure:
https://patentscope.wipo.int/search/en/result.jsf?inchikey=WYWIFABBXFUGLM-UHFFFAOYSA-N
- Australian Industrial Chemicals Introduction Scheme (AICIS)Phenol, 3-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethyl-https://services.industrialchemicals.gov.au/search-assessments/Phenol, 3-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethyl-https://services.industrialchemicals.gov.au/search-inventory/
- CAS Common ChemistryLICENSEThe data from CAS Common Chemistry is provided under a CC-BY-NC 4.0 license, unless otherwise stated.https://creativecommons.org/licenses/by-nc/4.0/
- ChemIDplusOxymetazoline [INN:BAN]https://pubchem.ncbi.nlm.nih.gov/substance/?source=chemidplus&sourceid=0001491594ChemIDplus Chemical Information Classificationhttps://pubchem.ncbi.nlm.nih.gov/source/ChemIDplus
- DrugBankLICENSECreative Common's Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/legalcode)https://www.drugbank.ca/legal/terms_of_useOxymetazolinehttps://www.drugbank.ca/drugs/DB00935
- EPA DSSToxOxymetazolinehttps://comptox.epa.gov/dashboard/DTXSID3040691CompTox Chemicals Dashboard Chemical Listshttps://comptox.epa.gov/dashboard/chemical-lists/
- European Chemicals Agency (ECHA)LICENSEUse of the information, documents and data from the ECHA website is subject to the terms and conditions of this Legal Notice, and subject to other binding limitations provided for under applicable law, the information, documents and data made available on the ECHA website may be reproduced, distributed and/or used, totally or in part, for non-commercial purposes provided that ECHA is acknowledged as the source: "Source: European Chemicals Agency, http://echa.europa.eu/". Such acknowledgement must be included in each copy of the material. ECHA permits and encourages organisations and individuals to create links to the ECHA website under the following cumulative conditions: Links can only be made to webpages that provide a link to the Legal Notice page.https://echa.europa.eu/web/guest/legal-noticeOxymetazolinehttps://chem.echa.europa.eu/100.014.618Oxymetazoline (EC: 216-079-1)https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/51171
- FDA Global Substance Registration System (GSRS)LICENSEUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.https://www.fda.gov/about-fda/about-website/website-policies#linking
- Hazardous Substances Data Bank (HSDB)OXYMETAZOLINEhttps://pubchem.ncbi.nlm.nih.gov/source/hsdb/3143
- Human Metabolome Database (HMDB)LICENSEHMDB is offered to the public as a freely available resource. Use and re-distribution of the data, in whole or in part, for commercial purposes requires explicit permission of the authors and explicit acknowledgment of the source material (HMDB) and the original publication (see the HMDB citing page). We ask that users who download significant portions of the database cite the HMDB paper in any resulting publications.http://www.hmdb.ca/citingOxymetazolinehttp://www.hmdb.ca/metabolites/HMDB0015070
- CCSbaseCCSbase Classificationhttps://ccsbase.net/
- ChEBI
- FDA Pharm ClassesLICENSEUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.https://www.fda.gov/about-fda/about-website/website-policies#linkingFDA Pharmacological Classificationhttps://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/ucm162549.htm
- NCI Thesaurus (NCIt)LICENSEUnless otherwise indicated, all text within NCI products is free of copyright and may be reused without our permission. Credit the National Cancer Institute as the source.https://www.cancer.gov/policies/copyright-reuseNCI Thesaurushttps://ncit.nci.nih.gov
- Open TargetsLICENSEDatasets generated by the Open Targets Platform are freely available for download.https://platform-docs.opentargets.org/licenceOXYMETAZOLINEhttps://platform.opentargets.org/drug/CHEMBL762
- ChEMBLLICENSEAccess to the web interface of ChEMBL is made under the EBI's Terms of Use (http://www.ebi.ac.uk/Information/termsofuse.html). The ChEMBL data is made available on a Creative Commons Attribution-Share Alike 3.0 Unported License (http://creativecommons.org/licenses/by-sa/3.0/).http://www.ebi.ac.uk/Information/termsofuse.htmlChEMBL Protein Target Treehttps://www.ebi.ac.uk/chembl/g/#browse/targets
- ClinicalTrials.govLICENSEThe ClinicalTrials.gov data carry an international copyright outside the United States and its Territories or Possessions. Some ClinicalTrials.gov data may be subject to the copyright of third parties; you should consult these entities for any additional terms of use.https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use
- Comparative Toxicogenomics Database (CTD)LICENSEIt is to be used only for research and educational purposes. Any reproduction or use for commercial purpose is prohibited without the prior express written permission of NC State University.http://ctdbase.org/about/legal.jspOxymetazolinehttps://ctdbase.org/detail.go?type=chem&acc=D010109
- Drug Gene Interaction database (DGIdb)LICENSEThe data used in DGIdb is all open access and where possible made available as raw data dumps in the downloads section.http://www.dgidb.org/downloadsCOMPOUND 20 [PMID: 23489211]https://www.dgidb.org/drugs/iuphar.ligand:8124ANTI-ILT7 ANTIBODYhttps://www.dgidb.org/drugs/iuphar.ligand:9124DITHIIPIN-1,1,4,4-TETROXIDE ANALOGUE 7https://www.dgidb.org/drugs/iuphar.ligand:6124ADENOPHOSTIN Ahttps://www.dgidb.org/drugs/iuphar.ligand:4124COMPOUND 19 [PMID: 19191557]https://www.dgidb.org/drugs/iuphar.ligand:3124
- IUPHAR/BPS Guide to PHARMACOLOGYLICENSEThe Guide to PHARMACOLOGY database is licensed under the Open Data Commons Open Database License (ODbL) https://opendatacommons.org/licenses/odbl/. Its contents are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License (http://creativecommons.org/licenses/by-sa/4.0/)https://www.guidetopharmacology.org/about.jsp#licenseGuide to Pharmacology Target Classificationhttps://www.guidetopharmacology.org/targets.jsp
- Therapeutic Target Database (TTD)Oxymetazolinehttps://idrblab.net/ttd/data/drug/details/D09EBS
- DailyMed
- Drugs and Lactation Database (LactMed)Oxymetazolinehttps://www.ncbi.nlm.nih.gov/books/n/lactmed/LM488/
- Mother To Baby Fact SheetsLICENSECopyright by OTIS. This work is available under the Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported license (CC BY-NC-ND 3.0).https://www.ncbi.nlm.nih.gov/books/about/copyright/
- Drugs@FDALICENSEUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.https://www.fda.gov/about-fda/about-website/website-policies#linkingOXYMETAZOLINEhttps://www.accessdata.fda.gov/scripts/cder/daf/
- NORMAN Suspect List ExchangeLICENSEData: CC-BY 4.0; Code (hosted by ECI, LCSB): Artistic-2.0https://creativecommons.org/licenses/by/4.0/OXYMETAZOLINENORMAN Suspect List Exchange Classificationhttps://www.norman-network.com/nds/SLE/
- EU Clinical Trials Register
- National Drug Code (NDC) DirectoryLICENSEUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.https://www.fda.gov/about-fda/about-website/website-policies#linking
- Japan Chemical Substance Dictionary (Nikkaji)
- KEGGLICENSEAcademic users may freely use the KEGG website. Non-academic use of KEGG generally requires a commercial licensehttps://www.kegg.jp/kegg/legal.htmlAnatomical Therapeutic Chemical (ATC) classificationhttp://www.genome.jp/kegg-bin/get_htext?br08303.kegTarget-based classification of drugshttp://www.genome.jp/kegg-bin/get_htext?br08310.kegRisk category of Japanese OTC drugshttp://www.genome.jp/kegg-bin/get_htext?br08312.keg
- MassBank Europe
- Metabolomics Workbench
- Nature Chemical Biology
- NIST Mass Spectrometry Data CenterLICENSEData covered by the Standard Reference Data Act of 1968 as amended.https://www.nist.gov/srd/public-lawOxymetazolinehttp://www.nist.gov/srd/nist1a.cfm
- SpectraBaseOxymetazolinehttps://spectrabase.com/spectrum/BhYgCAmnPoEOXYMETHAZOLINEhttps://spectrabase.com/spectrum/3XPMBXtyHJFOxymetazolinehttps://spectrabase.com/spectrum/C5rwT0hz0GY
- NLM RxNorm TerminologyLICENSEThe RxNorm Terminology is created by the National Library of Medicine (NLM) and is in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from NLM. Credit to the U.S. National Library of Medicine as the source is appreciated but not required. The full RxNorm dataset requires a free license.https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.htmloxymetazolinehttps://rxnav.nlm.nih.gov/id/rxnorm/7812
- WHO Anatomical Therapeutic Chemical (ATC) ClassificationLICENSEUse of all or parts of the material requires reference to the WHO Collaborating Centre for Drug Statistics Methodology. Copying and distribution for commercial purposes is not allowed. Changing or manipulating the material is not allowed.https://www.whocc.no/copyright_disclaimer/Oxymetazolinehttps://www.whocc.no/atc_ddd_index/?code=S01GA04Oxymetazolinehttps://www.whocc.no/atc_ddd_index/?code=R01AA05Oxymetazolinehttps://www.whocc.no/atc_ddd_index/?code=R01AB07Oxymetazolinehttps://www.whocc.no/atc_ddd_index/?code=D11AX27
- PharmGKBLICENSEPharmGKB data are subject to the Creative Commons Attribution-ShareALike 4.0 license (https://creativecommons.org/licenses/by-sa/4.0/).https://www.pharmgkb.org/page/policiesoxymetazolinehttps://www.pharmgkb.org/chemical/PA164748840
- PharosLICENSEData accessed from Pharos and TCRD is publicly available from the primary sources listed above. Please respect their individual licenses regarding proper use and redistribution.https://pharos.nih.gov/aboutoxymetazolinehttps://pharos.nih.gov/ligands/6U25T38G9QSZ
- Protein Data Bank in Europe (PDBe)
- RCSB Protein Data Bank (RCSB PDB)LICENSEData files contained in the PDB archive (ftp://ftp.wwpdb.org) are free of all copyright restrictions and made fully and freely available for both non-commercial and commercial use. Users of the data should attribute the original authors of that structural data.https://www.rcsb.org/pages/policies
- Springer Nature
- Thieme ChemistryLICENSEThe Thieme Chemistry contribution within PubChem is provided under a CC-BY-NC-ND 4.0 license, unless otherwise stated.https://creativecommons.org/licenses/by-nc-nd/4.0/
- Wikidataoxymetazolinehttps://www.wikidata.org/wiki/Q417813
- WikipediaOxymetazolinehttps://en.wikipedia.org/wiki/Oxymetazoline
- Wiley
- Medical Subject Headings (MeSH)LICENSEWorks produced by the U.S. government are not subject to copyright protection in the United States. Any such works found on National Library of Medicine (NLM) Web sites may be freely used or reproduced without permission in the U.S.https://www.nlm.nih.gov/copyright.htmlOxymetazolinehttps://www.ncbi.nlm.nih.gov/mesh/68010109Adrenergic alpha-Agonistshttps://www.ncbi.nlm.nih.gov/mesh/68000316Nasal Decongestantshttps://www.ncbi.nlm.nih.gov/mesh/68014663Sympathomimeticshttps://www.ncbi.nlm.nih.gov/mesh/68013566
- PubChem
- GHS Classification (UNECE)GHS Classification Treehttp://www.unece.org/trans/danger/publi/ghs/ghs_welcome_e.html
- MolGenieMolGenie Organic Chemistry Ontologyhttps://github.com/MolGenie/ontology/
- PATENTSCOPE (WIPO)SID 388397090https://pubchem.ncbi.nlm.nih.gov/substance/388397090